Fennec Pharmaceuticals (FENC) Equity Average (2016 - 2025)
Fennec Pharmaceuticals (FENC) has disclosed Equity Average for 15 consecutive years, with -$6.0 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average fell 83.13% year-over-year to -$6.0 million, compared with a TTM value of -$6.0 million through Sep 2025, down 83.13%, and an annual FY2024 reading of -$8.7 million, down 23.28% over the prior year.
- Equity Average was -$6.0 million for Q3 2025 at Fennec Pharmaceuticals, up from -$6.7 million in the prior quarter.
- Across five years, Equity Average topped out at $27.0 million in Q1 2021 and bottomed at -$11.1 million in Q4 2023.
- Average Equity Average over 5 years is $2.1 million, with a median of -$3.8 million recorded in 2024.
- The sharpest move saw Equity Average skyrocketed 165.55% in 2021, then tumbled 9607.73% in 2023.
- Year by year, Equity Average stood at $20.6 million in 2021, then crashed by 99.44% to $116500.0 in 2022, then crashed by 9607.73% to -$11.1 million in 2023, then skyrocketed by 50.15% to -$5.5 million in 2024, then dropped by 8.26% to -$6.0 million in 2025.
- Business Quant data shows Equity Average for FENC at -$6.0 million in Q3 2025, -$6.7 million in Q2 2025, and -$5.9 million in Q1 2025.